IMR Press / CEOG / Volume 44 / Issue 6 / DOI: 10.12891/ceog3903.2017

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Protein Z and anti-protein Z IgG levels, but not the promotor A13G polymorphism, are associated with preeclampsia
Show Less
1 Clinical Laboratory, Yijishan Hospital of Wannan Medical College, Wuhu, China
Clin. Exp. Obstet. Gynecol. 2017, 44(6), 929–933; https://doi.org/10.12891/ceog3903.2017
Published: 10 December 2017
Abstract

The present study was designed to determine the association between PZ promotor A13G polymorphism, PZ levels, anti-PZ antibodies levels, and the occurrence of preeclampsia (PE). A case-control study including normal pregnant women (control group, n=75) and pregnant women with PE (PE group, n=125) was performed. PZ levels (mg/L) were significantly lower in PE group (1.45 ± 0.21) than control group (2.07 ± 0.29, p < 0.05). The plasma anti-PZ IgG concentrations (AU/ml) in PE group (5.2 ± 0.62) were significantly higher than that in control group (3.3 ± 0.61, p < 0.05), while there were no significant differences of anti-PZ IgM concentrations (AU/ml) between two groups (12.2 ± 0.92 vs. 12.2 ± 1.18, p > 0.05). Multivariate analysis showed that decreased PZ [OR (95% CI) = 200.39 (11.80-3403.91)] and elevated anti-PZ IgG [OR (95% CI) = 0.013 (0.002-0.088)] were independent risk factors of PE. The results suggested that low PZ levels and high anti-PZ IgG levels are associated with the occurrence of PE.
Keywords
Preeclampsia
Protein Z
Anti-protein Z antibodies
Gene polymorphism
Share
Back to top